Impact of <i>PRKAA2</i> and <i>LKB1</i> genetic variants on metabolic alterations in response to metformin–sulfonylurea therapy
We conclude that <i>PRKAA2</i>(rs2746338) and <i>LKB1</i>(rs741765) variants were linked to favorable glycemic and lipid changes, suggesting reduced cardiovascular risk in T2DM. These variants may serve as pharmacogenetic markers for personalized therapy, warranting validation in larger studies.
Authors
- A Ansari (ORCID: https://orcid.org/0000-0001-6953-6119)
- Sushma Verma (ORCID: https://orcid.org/0000-0001-6705-161X)
- Aliya Abbas Rizvi (ORCID: https://orcid.org/0000-0002-8039-7081)
- Farzana Mahdi (ORCID: https://orcid.org/0000-0002-2188-2992)
- Mohammad Abbas (ORCID: https://orcid.org/0000-0002-9810-8313)
- Zeba Siddiqi
Institutions
- New Era University (PH)
Publication Details
- Journal
- Biomarkers in Medicine
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1080/17520363.2025.2608954
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00